Springworks wins fda approval for drug to treat desmoid tumors
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
The Food and Drug Administration on Monday approved the first treatment for people with desmoid tumors, a localized cancer that invades soft tissue and muscle. The new drug, called Ogsiveo,
is made by Springworks Therapeutics. It’s the company’s first approved medicine. Desmoid tumors are fibrous growths that start in connective tissue and are often found in the abdomen, arms,
legs, and torso. The tumors do not spread to other parts of the body but can cause severe disability and pain in the tissues that they impact, like muscle or nerves. There are no currently
approved therapies for desmoid tumors, but doctors often treat patients with chemotherapy, off-label targeted therapies, radiation, and surgery. STAT+ Exclusive Story Already have an
account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY COVERAGE AND ANALYSIS OF THE BIOTECH SECTOR — BY SUBSCRIBING TO STAT+. Already have an
account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe